GDUFA Performance Goals For Fiscal Years 2013-2017
By the end of the user fee cycle in FY 2017, FDA expects to have cleared the backlog and be acting on un-amended ANDA submissions with 10 months.
By the end of the user fee cycle in FY 2017, FDA expects to have cleared the backlog and be acting on un-amended ANDA submissions with 10 months.